deltatrials
Completed PHASE3 INTERVENTIONAL NCT00219804

Efficacy and Safety of Tetrabenazine in Chorea

A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's Chorea

Sponsor: Prestwick Pharmaceuticals

Conditions Huntington's Disease
Interventions tetrabenazine or placebo
Updated 4 times since 2017 Last updated: Sep 14, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Huntington's Disease and is currently completed. Prestwick Pharmaceuticals leads this study, which shows 4 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jan 2021 · 48 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2017 — Jan 2021 [monthly]

    Completed PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Prestwick Pharmaceuticals
Data source: Prestwick Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.